Actively Recruiting
Pregnenolone for the Treatment of Alcohol Use Disorder
Led by Yale University · Updated on 2026-02-02
150
Participants Needed
1
Research Sites
238 weeks
Total Duration
On this page
Sponsors
Y
Yale University
Lead Sponsor
N
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Collaborating Sponsor
AI-Summary
What this Trial Is About
This Phase 2 randomized cotrolled trial (RCT) will assess the safety and efficacy of pregnenolone (PREG; 300 mg/day, b.i.d dosing) vs. placebo (PBO) over a 12 week treatment period, and at 1-month post-treatment follow-up in individuals with Alcohol Use Disorder (AUD).
CONDITIONS
Official Title
Pregnenolone for the Treatment of Alcohol Use Disorder
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male and females, aged 18-70 years
- Regular weekly use of alcohol at least 3X weekly or more at treatment entry
- Must meet current DSM-5 criteria for moderate to severe Alcohol Use Disorders (AUDs) using SCID-I for DSM-5
- No health conditions that would impact trial participation as verified by screening and physical examination and absence of any of the exclusion criterions outlined below
- Able to read English and complete study evaluations
- Able to provide informed written and verbal consent
You will not qualify if you...
- Meet current criteria for moderate to severe substance use disorders from use of any other psychoactive substance, excluding nicotine and cannabis use disorder
- Current use of opioids
- Regular use of anticonvulsants, sedatives or hypnotics, oral prescription analgesics (other than non-steroidal anti-inflammatory drugs), topiramate, baclofen
- Regular use of steroidal supplements and steroid medications interacting with study medications based on clinical judgement of study physician (excluding hormonal contraceptives in women)
- Psychotic or otherwise severely psychiatrically disabled (i.e., suicidal, homicidal, current mania)
- Significant underlying medical conditions such as cerebral, renal, thyroid or cardiac pathology which in the opinion of study physician would preclude patient from fully cooperating or be of potential harm during the course of the study, but stable, prescribed anti-hypertensives. cardiovascular and diabetes medications will be allowed after review by study physician
- Any psychotic disorder or current Axis I psychiatric disorders requiring specific acute attention, including need for psychiatric medications, but stable, prescribed antidepressants and anti-anxiety medication to treat co-occurring psychiatric disorders will be allowed
- Women who are pregnant, nursing or refuse to use a reliable form of birth control (as assessed by urine pregnancy tests during initial medical evaluation, and assessed every two weeks during the course of the study)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The Yale Stress Center: Yale University
New Haven, Connecticut, United States, 06519
Actively Recruiting
Research Team
V
Verica Milivojevic, PhD
CONTACT
R
Rajita Sinha, PHD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here